Clinical Trial

A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to determine the effect of maridebart cafraglutide relative to placebo on insulin sensitivity in participants with Type 2 Diabetes Mellitus (T2DM) treated with stable dose of metformin.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-06-13
Trial Details
NCT Number NCT07160257
Lead Sponsor Amgen
Conditions Type 2 Diabetes Mellitus
Enrollment 56 participants
Start Date 2025-08-05
Primary Completion 2026-11-15 (estimated)
Study Completion 2027-03-04 (estimated)
Updated on ClinicalTrials.gov 2026-06-12